Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+/HER2- Advanced Breast Cancer|Targeted Therapy
Interventions: DRUG: Everolimus|DRUG: Chidamide|DRUG: Endocrine therapy|DRUG: Ovarian function suppression(OFS)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences